Oñate G, Garrido A, Arnan M, Pomares H, Alonso E, Tormo M, Diaz-Beya M, Vives S, Zamora L, Sampol A, Coll R, Salamero O, Cervera M, Garcia A, Vall-Llovera F, Garcia-Avila S, Bargay J, Ortin X, Iranzo E, Guijarro F, Pratcorona M, Nomdedeu JF, Esteve J, Sierra J
Diverse real-life outcomes after intensive risk-adapted therapy for 1034 AML patients from the CETLAM Group.
Sánchez R, Dorado S, Ruíz-Heredia Y, Martín-Muñoz A, Rosa-Rosa JM, Ribera J, García O, Jimenez-Ubieto A, Carreño-Tarragona G, Linares M, Rufián L, Juárez A, Carrillo J, Espino MJ, Cáceres M, Expósito S, Cuevas B, Vanegas R, Casado LF, Torrent A, Zamora L, Mercadal S, Coll R, Cervera M, Morgades M, Hernández-Rivas JÁ, Bravo P, Serí C, Anguita E, Barragán E, Sargas C, Ferrer-Marín F, Sánchez-Calero J, Sevilla J, Ruíz E, Villalón L, Del Mar Herráez M, Riaza R, Magro E, Steegman JL, Wang C, de Toledo P, García-Gutiérrez V, Ayala R, Ribera JM, Barrio S, Martínez-López J
Detection of kinase domain mutations in BCR::ABL1 leukemia by ultra-deep sequencing of genomic DNA (vol 12, 13057, 2022)
Heald JS, Méndez López A, Pato ML, Ruiz-Xiville N, Cabezón M, Zamora L, Vives S, Coll Jorda R, Maluquer Artigal C, Granada I, Sole F, Esteller M, Berdasco M
Identification of novel NUP98 fusion partners and co-mutations in Acute Myeloid Leukemia: an adult cohort study.
Salamero O, Molero A, Pérez-Simón JA, Arnan M, Coll R, Garcia-Avila S, Acuña-Cruz E, Cano I, Somervaille TCP, Gutierrez S, Arévalo MI, Xaus J, Buesa C, Limón A, Faller DV, Bosch F, Montesinos P
Iadademstat in combination with azacitidine in patients with newly diagnosed acute myeloid leukaemia (ALICE): an open-label, phase 2a dose-finding study.
Vives S, Quintela D, Morgades M, Cano-Ferri I, Serrano A, Acuña-Cruz E, Cervera M, Díaz-Beyá M, Vidriales B, Raposo-Puglia JÁ, Arnan M, Garrido A, Balerdi A, Cabello AI, Herrera-Puente P, Serrano J, Coll R, Tormo M, López-Marín J, García-Ávila S, Casado MS, Padilla I, Rodríguez-Macías G, Calbacho M, Puchol A, Hernández A, Torres M, Costilla L, Colorado MM, Martínez-Cuadrón D, Esteve J, Montesinos P
Salvage Therapy with Second-Generation Inhibitors for FLT3 Mutated Acute Myeloid Leukemia: A Real-World Study by the CETLAM and PETHEMA Groups.
Barba P, Morgades M, Montesinos P, Gonzalez-Campos J, Torrent A, Gil C, Bernal T, Tormo M, Mercadal S, Novoa S, García-Cadenas I, de Llano MPQ, Cervera M, Coll R, Bermudez A, Amigo ML, Monsalvo S, Esteve J, Garcia-Boyero R, Novo A, Hernandez Rivas JM, Cladera A, Martinez-Sanchez P, Serrano J, Artola MT, Soria B, Abella E, Vall-Llovera F, Bergua J, Herrera P, Barrios D, Ribera JM
Impact of Center-related Characteristics and Macroeconomic Factors on the Outcome of Adult Patients With Acute Lymphoblastic Leukemia Treated With Pediatric-inspired Protocols
Cruz D, Rodríguez-Romanos R, González-Bartulos M, García-Cadenas I, de la Cámara R, Heras I, Buño I, Santos N, Lloveras N, Velarde P, Tuset E, Martínez C, González M, Sanz GF, Ferrá C, Sampol A, Coll R, Pérez-Simón JA, López-Jiménez J, Jurado M, Gallardo D
LAG3 genotype of the donor and clinical outcome after allogeneic transplantation from HLA-identical sibling donors
Montoro MJ, Pomares H, Coll R, Bernal Del Castillo T, Tormo M, Jiménez A, Brunet S, Casaño J, Oiartzabal I, Díez-Campelo M, Ramos F, Romero R, Salido-Fiérrez E, Pedro C, Bargay J, Muñoz-Novas C, López R, Rafel M, Valcárcel D
Evaluation of the outcomes of newly diagnosed patients with high-risk myelodysplastic syndrome according to the initial therapeutical strategies chosen in usual clinical practice.
